These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30694615)

  • 21. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ferric Carboxymaltose in Heart Failure with Iron Deficiency.
    Mentz RJ; Garg J; Rockhold FW; Butler J; De Pasquale CG; Ezekowitz JA; Lewis GD; O'Meara E; Ponikowski P; Troughton RW; Wong YW; She L; Harrington J; Adamczyk R; Blackman N; Hernandez AF;
    N Engl J Med; 2023 Sep; 389(11):975-986. PubMed ID: 37632463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
    Hofmarcher T; Cabrales Alin D; Linde C
    Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.
    Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Sanchis J; Chorro FJ; Bayés-Genís A; Núñez J;
    Clin Cardiol; 2018 Jun; 41(6):729-735. PubMed ID: 29607528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial.
    Khalafallah AA; Yan C; Al-Badri R; Robinson E; Kirkby BE; Ingram E; Gray Z; Khelgi V; Robertson IK; Kirkby BP
    Lancet Haematol; 2016 Sep; 3(9):e415-25. PubMed ID: 27570088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iron deficiency in chronic and acute heart failure: A contemporary review on intertwined conditions.
    Cunha GJL; Rocha BML; Menezes Falcão L
    Eur J Intern Med; 2018 Jun; 52():1-7. PubMed ID: 29680173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
    Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating iron deficiency in patients with heart failure: what, why, when, how, where and who.
    Graham FJ; Guha K; Cleland JG; Kalra PR
    Heart; 2024 Sep; 110(20):1201-1207. PubMed ID: 39160066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Benson L; Fudim M; Corovic Cabrera C; Dahlström U; Rosano GMC; Jankowska EA; Anker SD; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Nov; 23(11):1844-1854. PubMed ID: 34476878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy.
    Cases Amenós A; Ojeda López R; Portolés Pérez JM;
    Nefrologia; 2017; 37(6):587-591. PubMed ID: 28610806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron deficiency in heart failure.
    Loncar G; Obradovic D; Thiele H; von Haehling S; Lainscak M
    ESC Heart Fail; 2021 Aug; 8(4):2368-2379. PubMed ID: 33932115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Heart failure and iron deficiency].
    Fava C; Piepoli M; Villani GQ
    G Ital Cardiol (Rome); 2019 Mar; 20(3):126-135. PubMed ID: 30821294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy.
    Froessler B; Gajic T; Dekker G; Hodyl NA
    Arch Gynecol Obstet; 2018 Jul; 298(1):75-82. PubMed ID: 29740690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
    J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.
    Anker SD; Kirwan BA; van Veldhuisen DJ; Filippatos G; Comin-Colet J; Ruschitzka F; Lüscher TF; Arutyunov GP; Motro M; Mori C; Roubert B; Pocock SJ; Ponikowski P
    Eur J Heart Fail; 2018 Jan; 20(1):125-133. PubMed ID: 28436136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aksan A; Işık H; Radeke HH; Dignass A; Stein J
    Aliment Pharmacol Ther; 2017 May; 45(10):1303-1318. PubMed ID: 28326596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The beneficial effects of iron supplementation other than improvement of anemia].
    Hamano T
    Rinsho Ketsueki; 2019; 60(9):1092-1099. PubMed ID: 31597832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact.
    Rognoni C; Gerzeli S
    J Comp Eff Res; 2019 Oct; 8(13):1099-1110. PubMed ID: 31580153
    [No Abstract]   [Full Text] [Related]  

  • 40. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.